Skip to content
DraconiticResearch
Search Sources API
201,683 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BYNew microbes and new infections

Molecular evidence of a dominant multidrug resistant Acinetobacter baumannii lineage in a tertiary hospital in northern Peru.

  • Kevin G Quispe Choque1
  • Nataly Ruiz Quiñones1
  • Milena Binatti Ferreira2
  • Ana L Perini-Leme-Giordano2
  • Angélica Zaninelli Schreiber3
  • Fabiana Fantinatti Garboggini2
  • Fanny L Casado4,5
  • Rene Flores Clavo4,5
5 affiliations
  1. 1Department of Biotechnology, Center for Research and Innovation in Multidisciplinary Active Sciences (CIICAM), Lambayeque, Peru.
  2. 2Division of Microbial Resources of Chemical, Biological and Agricultural Pluridisciplinary Research Center (CPQBA), University of Campinas, Sao Paulo, Brazil.
  3. 3School of Medical Sciences, University of Campinas, Campinas, Sao Paulo, Brazil.
  4. 4Bioengineering Section, Department of Engineering, Pontificia Universidad Católica del Perú, San Miguel, Lima, Peru.
  5. 5Instituto de Ciencias Ómicas y Biotecnología Aplicada, Pontificia Universidad Católica del Perú, San Miguel, Lima, Peru.
Read full textPDFDOICite

Abstract

Background

Acinetobacter baumannii is a major nosocomial pathogen because of its genomic plasticity and capacity to acquire multidrug resistance (MDR), particularly resistance to carbapenems. The World Health Organization classifies carbapenem-resistant A. baumannii as a critical-priority pathogen. Molecular epidemiological data from Latin America remain limited, especially for northern Peru.Methods

Drug-resistant A. baumannii isolates collected between 2015 and 2021 at a tertiary referral hospital in northern Peru were characterized by antimicrobial susceptibility testing, BOX-PCR, ERIC-PCR, REP-PCR, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).Results

All seven isolates met the criteria for MDR, and Ac-4268 showed an extensively drug-resistant phenotype. Repetitive-element PCR identified a group of six isolates with similar banding profiles and a divergent isolate, Ac-4268. Several isolates in the six-isolate group retained susceptibility to one or more aminoglycosides, whereas Ac-4268 was resistant to all antimicrobials tested. The combined molecular and phenotypic findings are consistent with the possible persistence of a dominant related lineage, but they do not establish transmission without whole-genome sequencing and epidemiological linkage data.Conclusion

This study provides additional molecular epidemiological evidence on MDR A. baumannii in northern Peru. The findings suggest that a dominant related lineage may have persisted in the hospital alongside a genetically divergent isolate with an extensively drug-resistant phenotype. Confirmation of clonal transmission requires higher-resolution genomic and epidemiological analyses.

Related

  1. Virulence determinants in multidrug-resistant Acinetobacter baumannii: comparative phenotypic and genomic analysis of clinical and patient-environmental isolates
    Preethi Basavaraju, Rashmi P. Mahale, Morubagal Raghavendra Rao +1
    Frontiers in cellular and infection microbiologyPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  2. Clinical characteristics, molecular features and in vitro susceptibility to sulbactam-durlobactam, cefiderocol, and eravacycline in NDM-1-producing versus OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates from children in Guangxi, China.
    Minxue Liu, Mengjun Li, Chenglan Yan +2
    Frontiers in cellular and infection microbiologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Outbreak of carbapenem-resistant Acinetobacter baumannii in post–haematopoietic stem cell transplantation patients potentially caused by drinking water contamination
    Xiaoyu Luo, Yinghua Zhang, Shihui Guo +6
    Infection prevention in practicePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Use of Tamoxifen Derivatives in Combination with Colistin against Colistin-Resistant Acinetobacter baumannii
    Irene Molina Panadero, Angela Rey Hidalgo, Isabella Rimoldi +3
    ACS OmegaPeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  5. Carbapenem-Resistant Acinetobacter baumannii Isolation and In-Hospital Mortality in Adults Hospitalized with COVID-19 in Romania: A Retrospective Single-Center Cohort Study
    Cristiana Georgeta Bujor, Marilena Dinuti, Felicia Sfrijan
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{choque2026molecular,
  title = {{Molecular evidence of a dominant multidrug resistant Acinetobacter baumannii lineage in a tertiary hospital in northern Peru.}},
  author = {Kevin G Quispe Choque and Nataly Ruiz Quiñones and Milena Binatti Ferreira and Ana L Perini-Leme-Giordano and Angélica Zaninelli Schreiber and Fabiana Fantinatti Garboggini and Fanny L Casado and Rene Flores Clavo},
  journal = {New microbes and new infections},
  year = {2026},
  month = oct,
  doi = {10.1016/j.nmni.2026.101864},
  url = {https://europepmc.org/article/MED/42926754},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Molecular evidence of a dominant multidrug resistant Acinetobacter baumannii lineage in a tertiary hospital in northern Peru.
AU  - Kevin G Quispe Choque
AU  - Nataly Ruiz Quiñones
AU  - Milena Binatti Ferreira
AU  - Ana L Perini-Leme-Giordano
AU  - Angélica Zaninelli Schreiber
AU  - Fabiana Fantinatti Garboggini
AU  - Fanny L Casado
AU  - Rene Flores Clavo
PY  - 2026
DA  - 2026/10/10
JO  - New microbes and new infections
DO  - 10.1016/j.nmni.2026.101864
UR  - https://europepmc.org/article/MED/42926754
AB  - Background  Acinetobacter baumannii is a major nosocomial pathogen because of its genomic plasticity and capacity to acquire multidrug resistance (MDR), particularly resistance to carbapenems. The World Health Organization classifies carbapenem-resistant A. baumannii as a critical-priority pathogen. Molecular epidemiological data from Latin America remain limited, especially for northern Peru.Methods  Drug-resistant A. baumannii isolates collected between 2015 and 2021 at a tertiary referral hospital in northern Peru were characterized by antimicrobial susceptibility testing, BOX-PCR, ERIC-PCR, REP-PCR, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).Results  All seven isolates met the criteria for MDR, and Ac-4268 showed an extensively drug-resistant phenotype. Repetitive-element PCR identified a group of six isolates with similar banding profiles and a divergent isolate, Ac-4268. Several isolates in the six-isolate group retained susceptibility to one or more aminoglycosides, whereas Ac-4268 was resistant to all antimicrobials tested. The combined molecular and phenotypic findings are consistent with the possible persistence of a dominant related lineage, but they do not establish transmission without whole-genome sequencing and epidemiological linkage data.Conclusion  This study provides additional molecular epidemiological evidence on MDR A. baumannii in northern Peru. The findings suggest that a dominant related lineage may have persisted in the hospital alongside a genetically divergent isolate with an extensively drug-resistant phenotype. Confirmation of clonal transmission requires higher-resolution genomic and epidemiological analyses.
SN  - 2052-2975
ER  -